Nautilus Biotechnology (NAUT)
(Delayed Data from NSDQ)
$2.74 USD
+0.10 (3.79%)
Updated May 31, 2024 04:00 PM ET
After-Market: $2.74 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NAUT 2.74 +0.10(3.79%)
Will NAUT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NAUT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAUT
Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know
NAUT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NAUT
Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Nautilus Biotechnology’s ESG Challenge: Navigating the Rising Tide of Corporate Responsibility Standards
Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...
Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript
NAUT Stock Earnings: Nautilus Biotechnology Beats EPS for Q1 2024